PALO VERDE HEALTH CARE DISTRICT REGULAR BOARD OF DIRECTORS MEETING MINUTES July 27, 2016 City Council Chambers
|
|
- Gwendolyn Freeman
- 5 years ago
- Views:
Transcription
1
2
3
4 PVHD BOD Meeting Minutes July 27, 2016 Page 1 of 6 PALO VERDE HEALTH CARE DISTRICT REGULAR BOARD OF DIRECTORS MEETING MINUTES July 27, 2016 City Council Chambers Directors Present Administrative Staff Present Sam Burton, Director Ms. Sandra Anaya, CEO Sandy Hudson, Director Ms. Christa Rohde, Assistant CFO Carmela Garnica, Director David Brooks, MD, Director TOPIC DISCUSSION ACTION 1.a. Call To Order Director Burton calls the meeting to order at approximately 5:04 p.m. 1.b. Pledge of Allegiance The Pledge of Allegiance was led by Director Brooks. M.D. 1.c. Roll Call Ms. Dakota Doyle conducts Roll Call. All members are present with the exception of Trina Sartin and Carmela Garnica. 2. Public Comment Director Burton calls for public comment. No public comment. 3. Approval of the Agenda Director Burton presents the Agenda for board consideration and approval. 4. Consent Agenda Director Hudson motions to approve the Agenda 3; Director Brooks seconds. Motion carried unanimously. 4.a. Review and Approval of Minutes from 6/22/ Medical Executive Committee Presented by Frank Arko, MD.,Chief of Staff 5.a. Verbal Medical Executive Committee Report and Updates Director Burton presents item 4.a. for board consideration and approval. Mohammad Bakhtavar, M.D. presents the Medical Executive Committee Report on behalf of Frank Arko, M.D. Mohammad Bakhtavar, M.D. reports that there are no Medical Executive Committee updates. Director Hudson motions to approve item 4.a.; Director Brooks seconds. Motion carried unanimously. 5.b. Credentialing and Reappointments Practitioner #5020 New Application Practitioner # New Application Practitioner # Mohammad Bakhtavar, M.D. presents item 5.b. for board consideration and approval in closed session. Prepared by D. Doyle 1
5 PVHD BOD Meeting Minutes July 27, 2016 Page 2 of 6 Reappointment Practitioner # Reappointment Practitioner # Reappointment 6. Reports 6.a. Board Report Presented by Trina Sartin, President No board report. [Director Carmela Garnica enters the meeting at approximately 5:08pm] 6.b. Administrative Updates Presented by Sandra Anaya, CEO Ms. Sandra Anaya reports item 6.b. and reports the following: Congressional visit by Dr. Raul Ruiz, 36 th District to PVH. o Congressman and his team were provided insight into the current issues affecting PVH and rural facilities. o Pledge to assist the hospital in several areas. Regulatory Compliance o CDPH Corrective Action Plan for May 2,3,4,5 Safety and Medication Error Reduction Plan [MERP] Licensing Survey was submitted and accepted; focus is on ensuring quarterly reporting and evaluation of MERP. o DNV Corrective Action Plan for May 13 and 14 survey was submitted and accepted. o Monitoring activities are in place, as follow up when needed. Program Updates o Designated Rural Status Awaiting word from DNV on how they can assist us. Spoke to Octavio Gonzalez, District Policy Director for Congressman Raul Ruiz. Will help us with CDHP if needed. PRIME Program o o o o Program provides incentives to improve the way care is delivered and to transition Alternative Payment Models. Plan was approved at the end of May, Preparing progress report which is due at end of September to provide initial planning activities. All eligible dollars paid to the hospital, other than IGT funds, are paid based on Prepared by D. Doyle 2
6 PVHD BOD Meeting Minutes July 27, 2016 Page 3 of 6 the hospital meeting the required performance measures. TCPI Program o Three [3] clinical health coaches were trained to help establish, coordinate and implement program activities. o Focus is on wellness and prevention for Medicare population. o Includes health screening and comprehensive care management. Diabetic Grant Program o On target with established milestones and reporting. o Will incorporate depression screening with use of evidence based tools. o Will continue to have monthly calls with program representative through HRSA. o Conference room will be utilized to start the health and wellness programs. o Diabetic Self-Management program will be implemented; Diabetic Educator will attend the Consortium Meeting on August 18 th to provide an overview of program activities. This will be a community program. Human Resource/Staff Development o Beta-rm ED Program Risk assessment will be conducted by Beta on August 30 and 31. Assessment is the foundation of their Quest for Zero program which focuses on improving outcomes in the ED to drive risk reduction. CE programs are associated with the program. Rural Trauma Class; presented by Abrazo o Course provided overview of immediate care for actual and potential trauma victims. o Staff knowledge will help with disaster planning as well. Radiology Contract Renewal o Terms of contract include Dr. Bowen being responsible for additional radiologic services and his own billing. o Hospital will pay a flat monthly rate. o Quality metrics are built-on for monitoring turnaround time. Policy o Updating Clinic policies o Starting to review Swing Bed standards Prepared by D. Doyle 3
7 PVHD BOD Meeting Minutes July 27, 2016 Page 4 of 6 and policy development. Human Resources o Having difficulty with recruitment of professional personnel: RN s, Lab Technologists. o Travelers also do not want to battle the heat. Plant Operations/Housekeeping o Final plans for CT have been submitted to OSHPD. If approved, bidding and advertising will be initiated. Want to get CT installed by first of year or shortly after. Directors Hudson and Garnica commented in regards to the article in the Palo Verde Times and that the hospital wasn t mentioned in Congressman Dr. Raul Ruiz s visit to Blythe. Ms. Anaya acknowledges and comments that she will write an article 6.c. Financial Updates Presented by Christa Rohde, Assistant CFO Ms. Christa Rohde reports item 6.c. and reports the following: IGT Funds were received this week approximately $430,000. Cash balance of approximately $2.1 million. Nearly done with the May charges in the new system. Goal is to have May, June and July financials completed by September 1 st. In regards to billing, wrapping up HMS this week with the expectation that HMS will not be accessible after August 1 st. All-Scripts billing is moving forward. Continuing to work with All-Scripts in building the patient module. Anticipate completing the payroll implementation in the next three weeks. o Including training for managers and employees on how to use the new system. 7. Action Items 7.a.Chief Executive Officer Agreement 7.b. Radiology Services Amendment Director Burton requests a motion to approve items 7.a., 7.b. and 7.c.. Director Hudson motions to approve item 7.a., 7.b., 7.c; Director Garnica seconds. Motion carried unanimously. Prepared by D. Doyle 4
8 PVHD BOD Meeting Minutes July 27, 2016 Page 5 of 6 7.c.Laboratory Director Agreement 7.d.Biennial Adoption of Conflict of Interest Code 8. Closed Session 8.a. Hospital Quality Assurance Report pursuant to Health & Safety Code b. Conference with Legal Counsel Existing Litigation Government Code (d) one case (1) Rutherford et al., v. PVHD, et al, USDC Case No.:EDCV JAK (OPx) 8.c. Conference with Legal Counsel concerning Potential Litigiation per Govt Code (d)(2) one case. 8.d. Report involving Trade Secret Discussion will concern proposed new services and facility. Estimated date of public disclosure: August Director Burton presents item 7.d. for board consideration and approval. Director Hudson makes a motion to table item 7.d. until further discussions with Ms. Sandra Anaya can take place. [The board steps out for closed session at approximately 5:30 p.m.] Director Hudson motions to table item 7.d.; Director Brooks seconds. Motion carried unanimously. 8.e.Credentialing for review and approval: Practitioner #5020 New Application Practitioner #5021 New Application Practitioner # Reappointment Practitioner # Reappointment Practitioner # Prepared by D. Doyle 5
9 PVHD BOD Meeting Minutes July 27, 2016 Page 6 of 6 Reappointment 9. Report After Closed Session Director Burton calls the meeting back to order at approximately 5:48 p.m. 10. Adjournment Director Burton adjourns the meeting at 5:49 p.m. Director Burton reports that the board voted and approved credentialing for practitioner #5020, practitioner #5021, practitioner #315152, practitioner #315229, and practitioner # The board took no further action in closed session. Sam Burton, Secretary Prepared by D. Doyle 6
10 Aminoglycoside Dosing Protocol Department: Pharmacy Function: Medication Management P & P Number: Pharmacy & Therapeutics 07/2016 Policy Protocol Procedure MEC Approval Date 07/2016 GB Approval Date 08/2016 Review Date 07/16 Initials AB I. Purpose: To provide a uniform and evidence based approach to aminoglycoside dosing. II. Affected Areas/Departments: All Departments that prescribe and dispense drugs. III. Policy The protocol is to standardize aminoglycoside therapy in order to maximize both safety and efficacy. IV. Procedure: A. The physician will assess the need for aminoglycoside therapy. Clinical factors such as results of the CBC and differential, C&S, gram stain, x-rays and the past and current status of the patient will be considered. B. When the physician wishes the pharmacy staff to regulate the aminoglycoside dosing, he/she should decide on the appropriate aminoglycoside to use (gentamicin, tobramycin, or amikacin) C. The physician should enter an order for Gentamicin Pharmacy to Dose, or Tobramycin Pharmacy to Dose or Amikacin Pharmacy to Dose in the EMR. After the pharmacist verifies the ordered request, he/she will obtain the following information from the patient s chart prior to initiation of therapy. 1. Height/weight 2. Age/sex 3. Serum creatinine/bun 4. CBC with differentials 5. Site of infection 6. Suspected/confirmed organisms (C&S) 7. Concurrent problems 8. Concurrent medications
11 9. Highest temperature for the past 24 hours D. If a recent serum creatinine is not available, appropriate lab tests may be ordered by the pharmacist as a part of the necessary baseline information. E. Based on the information obtained, an appropriate dose and interval will be calculated. The pharmacist will enter the order for the aminoglycoside in the EMR. A summary of the pharmacist assessment and recommendations shall be entered in the Progress Notes section of the EMR. F. If the pharmacist or physician determines that a change in dosage is necessary, the pharmacist will calculate a new regimen from the data available and discuss the results with the physician. G. Serum creatinine determination will be made every 3 days after the baseline level is known. The physician or pharmacist may order serum creatinine as often as necessary when the renal function changes or becomes unstable. H. The pharmacist will leave regular notes in the Progress Notes section of the EMR. These notes will inform the physician of the patient s progress. The physician does not have to be contacted verbally unless a significant change has occurred. V. EXTENDED-INTERVAL AG (also called once-daily ) THERAPY 1. The pharmacist will determine if the patient is a candidate for High-Dose aminoglycoside dosing. The following patient populations will be excluded from High-Dose therapy: 2. Pediatric (less than 18 years old) 3. Age greater than 60 years 4. Creatinine clearance less than 40ml/min 5. Pregnant 6. Burn patients 7. Patients with ascites 8. Dialysis patients 9. Enterococcal endocarditis 10. Febrile neutropenia B. Patient s estimated aminoglycoside elimination half-life is 5 hours or greater C. If the patient is a candidate for High_Dose aminoglcoside therapy the dose will be based on the patient s estimated Ideal Body Weight (IBW), rounded to the nearest 20mg for gentamicin/tobramycin, and 50mg for amikacin. 1. Standard gentamicin or tobramycin = 7mg/kg 2. Standard amikacin = 25mg/kg
12 3. The above doses are based on an assumed distribution volume = 0.3mg/kg. D. The goal of therapy is to achieve an aminoglycoside peak/mic ratio of at least 10:1. Larger or smaller doses may be desired depending on the volume of distribution of the patient and/or the MIC of the organism being treated. E. Order a single serum aminoglycoside concentration (SDS) 6 to 14 hours after the time the dose is administered. Refer to the nomogram (see below) to determine the dosing interval for gentamicin or tobramycin. Nomogram for assessment and adjustment of AG serum level following a 7mg/kg dose (Tobramycin and Gentamicin). Nicolau, et al. VI. CONVENTIONAL THERAPY VII. A. For conventional aminoglycoside dosing, determinations will be based on pharmacokinetic formulas listed in Appendix 2. B. Once therapy has been initiated, peak and trough levels obtained after the third dose to confirm the safety and the existence of the therapeutic concentrations. C. Trough levels: 30 minutes prior to the scheduled dose D. Peak levels: 1 hours after the IM dose or 30 minutes after completion of a 30 minute infusion E. Goals for peaks and troughs are found in the chart below. GOAL RANGES FOR AMINOGLYCOSIDE THERAPY (Conventional Dosing) Indication for therapy Gentamicin/Tobramycin Amikacin Peak (mcg/ml) Trough (mcg/ml) Peak (mcg/ml) Trough (mcg/ml)
13 Pneumonia 7 10 Less than Less than 10 Sepsis of 7 10 Less than Less than 10 unknown origin UTI sepsis 5 7 Less than Less than 10 Neutropenic 5 7 Less than Less than 10 fever Intraabdominal 5 7 Less than Less than 10 infection Complicated 5 7 Less than Less than 10 skin/soft tissue infection UTI/cystitis 4 6 Less than Less than 7 Synergy for gram positive endocarditis (gentamicin) 2 4 ~1
14 Vancomycin Dosing Protocol Department: Pharmacy Function: Medication Management P & P Number: Pharmacy & Therapeutics 07/2016 Policy Protocol Procedure MEC Approval Date 07/2016 GB Approval Date 08/2016 Review Date 07/16 Initials AB I. Purpose: To provide a safe and efficacious vancomycin therapy using evidence based practices. II. Affected Areas/Departments: All Departments that prescribe and dispense drugs. III. Policy Vancomycin orders will be assessed, dosed, and monitored by the Pharmacy department. IV. Procedure: A. When a physician places the order, Vancomycin per Pharmacy Dosing 1. A Pharmacist will assess the appropriateness of therapy and order initial laboratory values that aid in pharmacokinetic dosing 2. A nurse will a. Dosing guidelines found in APPENDIX A a. re-verify the patient s height in centimeters and weight in kilograms and call the Pharmacy with the values b. provide the dose to the patient as scheduled on the MAR B. Intravenous vancomycin will be given to adult patients, 18 years old C. Monitoring 1. Physicians will reassess the appropriateness of therapy daily a. Suspected adverse reactions will be reported to the physician for re-evaluation of drug therapy 2. Pharmacists will order laboratory values that monitor for safety and efficacy.
15 3. Laboratory personnel will obtain levels on schedule and verify the when the last dose of vancomycin before drawing blood Appendix A: Vancomycin Dosing Guidelines Background Vancomycin is a glycopeptide antibiotic used to treat penicillinase-producing strains of Staphyloccocus aureus and works by inhibiting bacterial cell wall synthesis. It has a timedependent bacteriocidal activity and is notorious for ototoxicity and nephrotoxicity. Before the advent of the Center for Drug Evaluation and Research (CDER), an organization responsible for approving proprietary drug names, vancomycin was known as brand name Vancocin - to take after the word vanquish. Vancomycin was also initially dubbed as Mississippi mud due to the impurities that gave it a brown color. Patient-specific Pharmacokinetic Parameters The patient-specific information that needs to be gathered for appropriate vancomycin dosing parameters are: 1) Height in centimeters 2) Weight in kilograms 3) Age in years 4) Sex 5) BUN 6) Serum creatinine 7) Complete blood count with differentials 8) Site of infection 9) Concurrent problems Before calculating any pharmacokinetics, it is important to identify if the patient falls into one of the following special populations: 1) obesity, actual body weight (ABW) 120% of ideal body weight (IBW); 2) hemodialysis; 3) pregnancy; 4) amputation. These populations have special considerations that must be weighed into their pharmacokinetic calculations. See APPENDIX B for the aforementioned special considerations. An equation list, located on APPENDIX C, will help estimate patient-specific pharmacokinetic parameters such as vancomycin clearance (CL vanco ), half-life (t 1/2 ), volume of distribution (V d ), elimination constant (k el ). These parameters will determine the patient s loading dose (LD), maintenance dose (MD), frequency of dosing (T), and rate of infusion (t in ). Loading Dose (LD): Do not delay a vancomycin loading dose because of pharmacokinetic calculations. Provide the patient with a single gram of vancomycin over one hour before estimating a loading dose. An additional dose, to appropriately load the patient, may be provided after the end of the first infusion. If one gram of vancomycin is more than the estimated loading dose, then it is still
16 clinically justified as the benefits of treating a serious gram-positive infection out-weigh the risk for nephrotoxicity. Provide the patient with vancomycin 1 gram IVPB over 1 hour initially, and then provide the patient with an additional dose immediately following the first gram to adequately load the patient (if necessary). The loading dose is calculated as where C p is the desired peak, 35 mg/l. Maintenance Dose (MD), Dosing Interval ( ), and Rate of Infusion (t in ): A maintenance dose is derived from the steady-state equation and assumes a desired vancomycin trough at steady-state, C ss,min, of 10 mg/l. A goal trough for deep seeded infections (pneumonia, osteomyelitis, endocarditis, and meningitis) is 15 to 20 mg/l. You will need the patient-specific pharmacokinetic parameters as well as the dosing interval and infusion time. The dosing interval is based on the patient-specific t 1/2 and is expressed as. T is 2 times the t 1/2. Choosing the nearest 8 hour interval may ease dosing administration. Selecting a rate of infusion, t in, is important in avoiding an infusion-related reaction known as Red Man Syndrome. This is likely to happen when 500 mg of vancomycin is infused in 30 minutes. For quantities 1 gram, infuse over 1 hour For quantities > 1 gram, infuse over 2 hours When determining the MD, we can use either the IV bolus model or short-infusion model. The short-infusion model applies to all situations of first-order kinetics. The IV bolus model is an abbreviated method that is valid when 6t in <t 1/2. IV bolus method: Short-infusion method: Revision of Initial Regimen Sudden changes in renal function and a subtherapeutic or supratherapeutic vancomycin trough warrants a revision of the dose.
17 Serum creatinine increases of >0.5 mg/dl (or 50%) suggests vancomycin-induced nephrotoxicity. When nephrotoxicity occurs, it is important to reassess the patient s antibiotic regimen with the physician staff and weigh the benefits of continuing therapy with the risks of severe adverse reactions. If vancomycin use is still appropriate, then draw a trough level just before the next due dose and hold the dose until the results return. Revise k el and determine a new regimen. Vancomycin troughs <10 mg/l encourages antibiotic resistance, while supratherapeutic vancomycin troughs between 30 to 65 mg/l has been associated with nephrotoxicity. If the vancomycin trough concentration is supratherapeutic or subtherapeutic, then the following questions must be answered 1. Was the value drawn appropriately? 2. Was this patient s renal function estimated appropriately? 3. Was this patient s vancomycin V d estimated incorrectly? Was the value drawn appropriately? An appropriately drawn vancomycin trough occurs 0.5 hours or less prior to the next administered dose, has prior administrations of vancomycin doses done as scheduled, and was drawn after the line was flushed. Investigate if these criteria have been met by contacting the corresponding responsible hospital staff. Failure to comply with appropriate draws warrants a medication error report (form PHPR3910), corrective feedback to staff, and a redraw of the vancomycin trough. Was this patient s renal function estimated appropriately? Patient s creatinine clearance is estimated using the Cockcroft-Gault equation and remembering to decrease it by 15 ml/min when the albumin is less than 3.0 mg/dl is easily missed when obtaining baseline pharmacokinetic parameters. If the patient s renal function has not changed, then re-estimate the creatinine clearance for the patient and see if it accounts for the out-of-range trough. The Cockcroft-Gault equation is not a perfect estimate of a patient s vancomycin clearance; errors in estimation occur mostly in obese and elderly patients. If the Cockcroft-Gault estimation does not clinically correlate with your patient, then revise k el and determine a new regimen. Was this patient s vancomycin V d estimated incorrectly? The volume of distribution is the most ignored pharmacokinetic parameter in vancomycin dosing and needs two post-distributive levels in order to evaluate. When predicted values are much greater or much less than the calculated value, it is warranted to use two post-distributive levels to calculate a new k el and V d. How to Revise a Regimen Method 1: Revising Cl vanco If the renal function has changed or if the trough was slightly under or over-estimated, then this method is recommended. First provide a best estimate for steady-state peak and trough (C ss,max and C ss,min respectively).
18 1., where C meas is the value obtained ½ hour prior to the next dose It is easier for the laboratory technicians and nurses to time the trough a half-hour prior to the next dose, hence the 0.5hr value in the equation above. Adjust the elapsed time based on how close the trough was drawn with respect to the next dose. 2. Revise the k el and assume that the IV bolus model is valid. 3. Recalculate the patient specific pharmacokinetic parameters using the new k el and original V d, and adjust the regimen. Method 2: Revising V d If the patient s renal function has not changed and the trough was grossly under or overestimated, then this method is recommended. Use the best steady-state peak and trough (C ss,max and C ss,min respectively) using the steady-state equation. Then calculate the new volume of distribution using the new elimination constant and the best peak and trough estimates. Recalculate the patient specific pharmacokinetic parameters using the new V d and original Cl vanco, and adjust the regimen. Monitoring Toxicity Common toxicities with vancomycin include red man syndrome, nephrotoxicity, and ototoxicity. Red man syndrome is associated with a histamine release and manifests as tingling and flushing of the face, neck, and upper torso during rapid infusions of >500 mg of vancomycin over 30 minutes. Vancomycin as a monotherapy antibiotic has an incidence of nephrotoxicity between 5 to 7%. Reported incidence has increased with concomitant use of aminoglycosides or other nephrotoxic agents. There is no established evidence that maintaining vancomycin serum concentrations within a given range can prevent nephrotoxicity. In addition nephrotoxicity with
19 this drug has been associated with older age, longer treatment courses, and higher serum trough concentrations (30 to 65 mg/l). Vancomycin destruction of glomeruli and necrosis of the proximal tubule are thought to be due to oxidative stress that is usually reversibly. The reported incidence of vancomycin-induced ototoxicity is between 1 to 9% and has been associated with serum concentrations above 40 mg/l. It is characterized as damage to the auditory nerve that initially affects high-frequency sensory and then middle and low frequency sensory. High-tone deafness occurs before low-tone deafness at all frequencies and is permanent. Nevertheless, severe ototoxicity from this drug is rare, and monitoring of serum vancomycin levels to prevent ototoxicity is not recommended. The following parameters will be used to monitor for vancomycin toxicity: 1. Daily serum creatinine hour urine output 3. BUN 4. Renal specific electrolytes: potassium, magnesium, and phosphorous Efficacy In 2006, the Clinical and Laboratory Standards Institution (CLSI), lowered the susceptibility of vancomycin to minimum inhibitory concentrations (MIC) 2 mg/l. There is little data showing that appropriate vancomycin dosing reduces mortality in patients infected with MRSA, however vancomycin serum troughs of <10 mg/l may predict therapeutic failure and the potential for vancomycin resistance. It is advised to continue vancomycin therapy if the sensitivities show an MIC 1 mg/l and an achievable area under the curve (AUC) to MIC ratio can be sustained at Cultures and sensitivities a. Minimum inhibitor concentration (MIC) >1 is a strong predictor of vancomycin failure 2. Area under the curve by adding Lin trap and Log trap together and account for a 24 hour dose. The AUC 0-24hr to MIC ratio must be greater than Vancomycin trough a. Should be drawn no sooner than at steady-state b. With prolonged use (>5 days), it is reasonable to monitor a vancomycin trough once weekly Appendix B: Vancomycin Special Considerations
20 Obesity In patients with a total body weight (TBW) 120% of ideal body weight (IBW), but not 300% of IBW, it is best to use the Leonard and Boro model and adjusted body weight (ABW) to calculate vancomycin clearance. Providing obese patients with 15 mg/kg every 8-12 hours may lead to supratherapeutic levels. It is recommended to stay within either: 1) 10 mg/kg every 12 hours using TBW 2) 15 mg/kg every 24 hours using TBW Hemodialysis PHLB contracts with Davita Dialysis that provides hemodialysis with the 2008K 2 Hemodialysis by Fresenius Medical Care. It is anticipated that one-third of vancomycin is pulled per hemodialysis session. Amputees These populations have special considerations that must be weighed into their pharmacokinetic calculations. When calculating their clearance, it is best to use their IBW based on how tall they were originally. Pharmacokinetic Parameter Ideal Body Weight, IBW Adjusted Body Weight, ABW Estimated Creatinine Clearance, CrCl Equation Variables Comments x h TBW SF wt Resulting units expressed in kilograms height in inches Total Body Weight resulting units expressed as ml/min
21 Pharmacokinetic Parameter Vancomycin Clearance, Cl vanco Volume of distribution, V d Elimination constant, k el Half-life, t 1/2 Equation Variables Comments use ABW if obese, otherwise use IBW Leonard and Boro model If CrCl 60ml/min If CrCl <60ml/min
22
23
24
25
26
27
28
29
Adult Institutional Pharmacokinetics Protocol
Adult Institutional Pharmacokinetics Protocol Policy Title: Clinical Pharmacokinetics (PK) Service Policy Policy Statement: It is the policy of UMHC that PK consult orders (for vancomycin or aminoglycosides)
More informationPolicy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More information(Max 2 g) = to nearest 250 mg
Appendix 1 (part 1 of 8): Rubric for competency assessment of pharmacists prescribing and managing vancomycin Empiric Dosing Phase Pts Yes No Data Error OP Did the pharmacist document the indication 2
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationINTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS
Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title
More informationEDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley
More informationClinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)
VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationAMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES
Approved: September 2017 AMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee GENERAL COMMENTS Aminoglycosides (AG) include gentamicin,
More informationPHA5128 Dose Optimization II Case Study 3 Spring 2013
Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What
More informationAdult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016
Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology
More informationBSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin
BSWH Pharmacist Continuing Education 2015 PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin Objectives Define basic pharmacodynamic and pharmacokinetic principles Describe
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationApproved by: SMG Origination Date: 06/14 Expiration Date: 06/17 Review Date: Revision Date: POLICY and PROCEDURE Archived Date: Page 1 of 14
POLICY and PROCEDURE Archived Date: Page 1 of 14 PURPOSE In order to provide consistent and optimal vancomycin and aminoglycoside dosing and monitoring, a pharmacokinetic (PK) service will be provided
More informationNHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion
Acute Sector NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion Co-ordinators: Gillian Macartney Fiona McDonald Specialist Antibiotic
More informationIV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro
IV Vancomycin dosing and Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary Medicine Unique
More informationAminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive
Aminoglycosides Uses: Treatment of serious gram-negative systemic infections and some grampositive infections such as infective endocarditis. Disadvantage: aminoglycosides are their association with nephrotoxicity
More informationMEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol
I. PURPOSE MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol To allow standardized pharmacist management of IV vancomycin in the inpatient setting using evidence-based guidelines
More informationAminoglycosides John A. Bosso, Pharm.D.
AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly
More informationSBUH Aminoglycoside Dosing Protocol
Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationCystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More informationD DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1.
Journal of Pharmacy and Pharmacology 2 (2014) 713-721 doi: 10.17265/2328-2150/2014.12.004 D DAVID PUBLISHING Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within
More informationPHARMACOKINETICS SMALL GROUP II:
PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state
More informationInitiating Aminoglycosides Safely. Last updated: July 2016, Version 5 Questions/Comments?
Initiating Aminoglycosides Safely Last updated: July 2016, Version 5 Questions/Comments? Email Mark.McIntyre@uhn.ca Click orange buttons to navigate protocol. Index: Aminoglycoside Dosing Algorithms Objective
More informationClinical Study Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations
Interdisciplinary Perspectives on Infectious Diseases Volume 2013, Article ID 839456, 8 pages http://dx.doi.org/10.1155/2013/839456 Clinical Study Prospective Trial of a Novel Nomogram to Achieve Updated
More informationChallenges in Therapeutic Drug Monitoring:
Challenges in Therapeutic Drug Monitoring: Focus on Vancomycin Pharmacodynamics and Pharmacokinetics Katherine Gallaga, PharmD PGY1 Pharmacy Practice Resident CHRISTUS Spohn Health System 1 Pharmacist
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationVancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy
Vancomycin Pharmacokinetics Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy Goals Review the PK properties of vancomycin Compare and contrast methods of dosage regimen design for vancomycin
More informationClinical Safety & Effectiveness Cohort # 10
1 Clinical Safety & Effectiveness Cohort # 10 Improving Weight-Based Vancomycin Dosing and Monitoring DATE Educating for Quality Improvement & Patient Safety 2 Financial Disclosure lizabeth A. Walter,
More informationEvaluation of Vancomycin Continuous Infusion in Trauma Patients
OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential
More informationCareer Corner: Pharmaceutical Calculations for Technicians. Ashlee Mattingly, PharmD, BCPS
Career Corner: Pharmaceutical Calculations for Technicians Ashlee Mattingly, PharmD, BCPS Disclosure I have no actual or potential conflict(s) of interest in relation to this program. Learning Objectives
More informationpharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.
Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration
More informationIMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:
IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE: IMPACT OF A PHARMACY DEPARTMENT-WIDE APPROACH IN A COMMUNITY HOSPITAL SETTING November 2014 Monica Dorobisz,
More informationTHE AMINOGLYCOSIDE ANTIBIOTICS
4 THE AMINOGLYCOSIDE ANTIBIOTICS INTRODUCTION The aminoglycoside antibiotics are widely used for the treatment of severe gram-negative infections such as pneumonia or bacteremia, often in combination with
More informationASHP Therapeutic Position Statements 623
ASHP Therapeutic Position Statements 623 Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society
More information(telavancin) Healthcare Professional s Guide. Version 2, 4 November 2014
VIBATIV (telavancin) Healthcare Professional s Guide Version 2, 4 November 2014 1 Table of Contents Introduction... 3 About Vibativ / Therapeutic indications... 3 Antimicrobial spectrum of activity for
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationSetting The setting was hospital and the economic analysis was carried out in the Netherlands.
Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis van Lent-Evers N A, Mathot R A, Geus W P, van Hout B A, Vinks
More informationVancomycin Drug Class 1
Drug Class 1 Antibiotic glycopeptide Spectrum 1 Cross Sensitivities / Allergies 1 Refer to product monograph for complete spectrum Gram positive pathogens (e.g., S. aureus, Enterococcus, S. viridans, methicillinresistant
More informationPHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq
PHARMONITOR II Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling Pierre Wallemacq NATIONAL SYMPOSIUM 20 years EEQ Leuven, March 26th 2009 1 Why monitoring of aminoglycosides?
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationExperience with a Once-Daily Aminoglycoside Program Administered to 2,184 Adult Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1995, p. 650 655 Vol. 39, No. 3 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology Experience with a Once-Daily Aminoglycoside Program Administered
More informationBassett Healthcare Clinical Laboratory
Therapeutic Drug Level Collection Guidelines Anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, primidone, valproic acid) Consider collecting after steady state conditions are reached, i.e.
More informationECN Protocol Book. Generic Chemotherapy Protocol Guidelines. ECN_Protocol_Book_generic chemotherapy protocol guidelines guidelines_1
ECN Protocol Book Generic Chemotherapy Protocol Guidelines Name of person presenting document: Reason for document development: Names of development team: Specify groups of staff to whom the document relates:
More informationAssessing Renal Function: What you Didn t Know You Didn t Know
Assessing Renal Function: What you Didn t Know You Didn t Know Presented By Tom Wadsworth PharmD, BCPS Associate Clinical Professor UAA/ISU Doctor of Pharmacy Program Idaho State University College of
More informationCARBOplatin (AUC5) and Etoposide 100mg/m 2 Therapy-21 day
INDICATIONS FOR USE: CARBOplatin (AUC5) and 100mg/m 2 Therapy-21 day ICD10 Regimen Code INDICATION Small cell lung cancer (SCLC) extensive disease C34 00271a *If a reimbursement indicator (e.g. ODMS, CDS
More informationNephrotoxicity. Pros and Cons of the article: Relationship between Initial Vancomycin
Pros and Cons of the article: Relationship between Initial Vancomycin Nephrotoxicity among Hospitalized Patients Diane M. Cappelletty, Pharm.D. Associate Professor Pharmacy Practice The University of Toledo
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationVancomycin Orion , Version 2 Public Summary of the Risk Management Plan
Vancomycin Orion 18.1.2016, Version 2 Public Summary of the Risk Management Plan VI.2 Elements for a Public Summary Vancomycin Orion is intravenously administered glycopeptide antibiotic. It is indicated
More informationStRs and CT doctors in haematology. September Folinic acid dose modified.
High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH
More informationLung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationJoint Trust Guideline for the Use of Intravenous Vancomycin in Paediatrics
A clinical guideline recommended For use in: All clinical areas where vancomycin is prescribed for Children aged 1 month to 16 years By: All medical, nursing, pharmacy, microbiology and phlebotomy paediatric
More informationModifying Drug Dosing for Patients with Renal Insufficiency
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-pharmacy/modifying-drug-dosing-for-patients-with-renalinsufficiency/3427/
More informationCisplatin Vinorelbine (Oral) therapy +/- radiotherapy
1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer
More informationPPP 1. Continuation, modification, and discontinuation of a medication
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationCisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck
Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck Indication: 1) Concomitant chemo-radiotherapy for locally advanced squamous cell carcinoma head and neck 2) Post-operative
More informationPublic Assessment Report Scientific discussion. Vancomycin Farmaplus Vancomycin hydrochloride SE/H/1158/01-02/MR
Public Assessment Report Scientific discussion Vancomycin Farmaplus Vancomycin hydrochloride SE/H/1158/01-02/MR This module reflects the scientific discussion for the approval of Vancomycin Farmaplus 500
More informationSelected Clinical Calculations Chapter 10. Heparin-Dosing calculations
Selected Clinical Calculations Chapter 10 Heparin-Dosing calculations Heparin is a heterogeneous group of muco-polysaccharides that have anticoagulant properties (slows clotting time). Heparin salt, as
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationGuideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use
Guideline for the Management of Continuous IV Vancomycin Infusion in A Clinical Guideline recommended for use For Use in: By: For: Division responsible for document: Key words: Name and job title of document
More informationNorth Dakota Board of Pharmacy
North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives
More informationPHA 5128 Spring 2000 Final Exam
PHA 128 Spring 2000 Final Exam On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name TYPED KEY Questions Points 1. /1 2. /1 3. /1 4. /1. /10 6. /10. /10 8. /10
More informationPHA 5128 Spring 2009 First Exam (Version B)
Name: UFID: PHA 5128 Spring 2009 First Exam (Version B) On my honor, I have neither given nor received unauthorized aid in doing this assignment. Print: Sign: Version B Q1: Phenytoin (10) Q2: procainamide
More informationGENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC SETTINGS GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC
GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC SETTINGS 1 1 Gentamicin: Guidelines for Once Daily Usage in Adult and Paediatric Settings These guidelines were designed by the Gentamicin
More informationVancomycin: Class: Antibiotic.
Vancomycin: Class: Antibiotic. Indications: Treatment of patients with infections caused by staphylococcal species and streptococcal Species. Available dosage form in the hospital: 1G VIAL, 500MG VIAL.
More informationLung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationNCCP Chemotherapy Regimen. Carboplatin (AUC 2) Weekly with Radiotherapy (RT)
INDICATIONS FOR USE: Carboplatin (AUC 2) Weekly with Radiotherapy (RT) Regimen Code 00419a *Reimbursement Indicator INDICATION ICD10 Chemoradiation treatment for stage III and IV locally advanced C11 nasopharyngeal
More informationIntravenous Vancomycin Use Adult Inpatient/Ambulatory Clinical Practice Guideline
Intravenous Vancomycin Use Adult Inpatient/Ambulatory Clinical Practice Guideline Table of Contents INTRODUCTION... 3 SCOPE... 3 RECOMMENDATIONS... 5 TABLE 1. EMPIRIC INTERMITTENT VANCOMYCIN DOSING NOMOGRAM...
More informationTDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages
TDM Lecture 8 5 th Stage TDM of Digoxin Use of Digoxin Serum Concentrations to Alter Dosages Linear Pharmacokinetics Method This method is used in steady-state condition. We compute the new dose of digoxin
More informationprophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures
1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationVancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1982, p. 575-58 66484/82/4575-6$2./ Vol. 21, No. 4 Vancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects ROBERT A. BLOUIN,1 LARRY A. BAUER,3* DELWYN
More informationCubicin A Guide to Dosing
Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections
More informationPRINCIPLES OF PEDIATRIC PHARMACOTHERAPY. Marianne Krupicka, Pharm.D. Oregon Health and Science University/ Doernbecher Children s Hospital
PRINCIPLES OF PEDIATRIC PHARMACOTHERAPY Marianne Krupicka, Pharm.D. Oregon Health and Science University/ Doernbecher Children s Hospital References Pediatric Lexicomp Harriett Lane Respiratory Rate Newborn
More informationVancomycin Orion , Version 1.0. Public Summary of the Risk Management Plan
Vancomycin Orion 18.6.2015, Version 1.0 Public Summary of the Risk Management Plan VI.2 Elements for a Public Summary Vancomycin Orion is intravenously administered glycopeptide antibiotic. It is indicated
More informationAdult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.
AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough
More informationImpact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review
Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 584 608 doi: 10.1111/jcpt.12200 Review Article Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive
More informationVANCOCIN CAPSULES (vancomycin hydrochloride)
PRODUCT INFORMATION VANCOCIN CAPSULES (vancomycin hydrochloride) This preparation for the treatment of colitis is for oral use only. Vancocin must be given orally for treatment of staphylococcal enterocolitis
More informationMortality Rate was unsightly!!! 4/24/2013. Sepsis Quality Improvement Project
Libby, MT Sepsis Quality Improvement Project Barb Dumont RN, Director of Quality and Risk Management Mike Julius RN, ED Manager Cathy Wolfe RN, Chief Nursing Officer. Mortality Rate was unsightly!!! percent
More informationCARBOplatin (AUC1.5) Chemoradiation Therapy-7 days
CARBOplatin (AUC1.5) Chemoradiation Therapy-7 days INDICATIONS FOR USE: Regimen Code INDICATION ICD10 Chemoradiation commencing 3 to 8 weeks after the completion of induction chemotherapy with TPF in patients
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationCisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix
Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix Indication: Neoadjuvant chemotherapy followed by Chemo-radiotherapy in Small Cell Carcinoma
More informationROSOBAC-1GM / ROSOBAC-FORT
ROSOBAC-1GM / ROSOBAC-FORT ROSOBAC - 1GM. COMPOSITION : Each vial contains Sterile Cefoperazone Sodium IP Eq. to Anhydrous Cefoperazone - Sterile Sulbactam Sodium USP Eq. to Anhydrous Sulbactam - ROSOBAC
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationPHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5128 Final Exam Spring 2004 Version A On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name There are 18 questions. Total /120 pts Final 2004 1 1. T.P., a 66-year-old,
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationDrug Prescribing. Ravi Menon
Drug Prescribing Ravi Menon Introduction Approximately 7,000 individual drug doses are administered each day in a 'typical' NHS hospital, 70% of which are prescribed by first year graduates and senior
More informationSECTION PRESCRIPTIONS
SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or
More informationPharmacodynamic indices in targeting therapy of critical infections
Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective
More informationPHARMACOKINETICS SMALL GROUP I:
PHARMACOKINETICS SMALL GROUP I: Question 1 Absorption of the anti-fungal agent, itraconazole, is dependent on a low gastric ph. Calculate the relative concentrations of a weak acid (with a pka of 5.4)
More information